The Physics of Cancer: How Myosin Therapeutics is Rewriting Oncology's Rules

JUPITER, Fla. – October 16, 2026 – For nearly two decades, the pharmaceutical industry has thrown billions of dollars at glioblastoma (GBM), only to watch one of the most aggressive forms of brain cancer outsmart virtually every biochemical roadblock placed in its path. Since the approval of bevacizumab in 2008, the landscape of GBM treatment has been characterized by a frustrating series of clinical trial failures, leaving patients with grim prognoses and investors wary of neuro-oncology ventures. But a fundamental shift is quietly taking root in the biotechnology sector—one that moves away from targeting mutable chemical signaling pathways and instead attacks the physical, mechanical structures that tumors rely on to survive.

At the forefront of this shift is Myosin Therapeutics, a clinical-stage biotechnology company that announced today its selection as a 2026–2027 National Cancer Institute (NCI) SBIR Investor Initiatives Showcase Company. This prestigious backing has paved the way for the company's featured presentation at BioFuture 2026, taking place October 27–28 in New York City. The invitation serves as both a scientific validation and a critical business milestone as the company prepares its lead candidate, MT-125, for Phase 2 dose expansion.

As the broader economy grapples with cautious venture capital deployment, particularly in high-risk life sciences, Myosin's approach illustrates how early-stage biopharmas are leveraging novel science and government validation to navigate the notoriously difficult "valley of death" between early clinical trials and late-stage commercialization.

The Physics of Cancer: Disrupting Cellular Nanomotors

Historically, the dominant paradigm in oncology has been to identify and block the specific biochemical signaling cascades that drive tumor growth. The fatal flaw in this approach, particularly with highly mutable cancers like glioblastoma, is the tumor's ability to develop resistance. When one pathway is blocked, the cancer simply rewires its internal circuitry to find a new route to proliferation.

Myosin Therapeutics is pioneering a radically different approach known as mechanobiology. Instead of playing biochemical whack-a-mole, the company's lead drug candidate, MT-125, is designed as a first-in-class non-muscle myosin inhibitor. The drug targets non-muscle myosin II (NMII) paralogs—microscopic motor proteins that act as the physical engine of the cell. These molecular nanomotors regulate the cytoskeleton, driving the physical mechanics required for cancer cells to move, divide, invade healthy brain tissue, and maintain mitochondrial function.

"Glioblastoma is the proving ground for a new way to treat cancer, selectively preventing the physical mechanics tumor cells depend on to grow and survive, rather than targeting signaling pathways that tumors learn to bypass," said Dr. Courtney Miller, Chief Executive Officer of Myosin Therapeutics.

By inhibiting NMII, MT-125 effectively triggers a catastrophic structural collapse within the tumor cell. Because this mechanism relies on disrupting fundamental physical dependencies rather than redundant chemical signals, preclinical models suggest it is far more difficult for the cancer to develop resistance. The foundational science backing this approach has been validated in two peer-reviewed publications in the journal Cell, demonstrating that this mechanical disruption can selectively target aggressive cancers without inducing unacceptable systemic toxicity in healthy tissues.

Tackling Brain Cancer's Hardest Frontier

The clinical testing ground for this novel mechanism is the ongoing STAR-GBM trial (NCT07185880), an NCI-supported Phase 1/2 study currently enrolling patients at Mayo Clinic sites in Florida, Arizona, and Minnesota. The trial's design reflects a highly targeted clinical strategy aimed at the most vulnerable and underserved patient population in the neuro-oncology space.

STAR-GBM is specifically enrolling adults with newly diagnosed, IDH wild-type, MGMT unmethylated glioblastoma. The MGMT promoter methylation status is a critical biomarker in brain cancer. Patients with unmethylated MGMT typically do not respond to temozolomide (TMZ), the current standard-of-care chemotherapy. By focusing exclusively on this subpopulation, Myosin is addressing an area of profound unmet medical need, justifying the exclusion of TMZ from the trial protocol and evaluating MT-125 in combination with standard radiotherapy alone.

The trial utilizes a sophisticated Bayesian Optimal Interval (BOIN) design for its Phase 1 portion. This statistical approach allows researchers to efficiently evaluate up to four dose levels to identify the maximum tolerated dose (MTD) with a high degree of safety and precision. Once the MTD is established, the trial will seamlessly transition into a randomized, parallel dose expansion cohort in Phase 2.

The FDA has already signaled its recognition of the drug's potential, granting MT-125 both Orphan Drug Designation for malignant gliomas and Fast Track Designation for glioblastoma. These regulatory designations are critical economic drivers, offering potential market exclusivity, tax credits for clinical research, and a streamlined pathway for FDA interactions—assets that significantly enhance the program's value proposition for prospective investors.

Biotech Partnering at a Crossroads

Beyond the science, Myosin's upcoming presence at BioFuture 2026 highlights the intricate dance of biotech financing in the modern economy. BioFuture, produced by Demy-Colton, is a premier nexus for innovators and investors aiming to shape the future of biopharma. On October 27, Dr. Miller will take the stage on the panel "Beyond the Cure: The Brave New World of Revolutionary Cancer Therapeutics," sharing the spotlight with leaders in next-generation cell therapies and AI-enabled drug discovery.

Simultaneously, Dr. Karen Smith, Myosin's Chief Medical Officer, will be conducting one-on-one investor and strategic partner meetings. The goal is clear: secure the capital and pharmaceutical partnerships necessary to propel MT-125 beyond brain cancer.

In the current macroeconomic climate, life sciences venture capitalists are increasingly risk-averse, demanding robust de-risking before committing Series A or B capital. Myosin has strategically built a fortress of non-dilutive validation to meet this demand. Being handpicked for the NCI SBIR Investor Initiatives Showcase is a powerful signal to the private market that the underlying science has survived rigorous federal vetting. Furthermore, the company recently secured a $2 million grant from the Casey DeSantis Florida Cancer Innovation Fund to support its Mayo Clinic operations in Jacksonville, highlighting Florida's aggressive push to establish itself as a premier biotechnology hub.

As one life sciences venture capitalist observing the neuro-oncology space recently noted, non-dilutive validation has become the new currency in biotech, providing the necessary runway for companies to prove their clinical endpoints without prematurely diluting early shareholders.

The strategic vision for Myosin extends far beyond the STAR-GBM trial. The company views glioblastoma not as the final destination, but as the ultimate proving ground. Because the physical mechanics of tumor growth are conserved across multiple types of aggressive malignancies, the company plans to leverage the safety and efficacy data from the current trial to support the expansion of MT-125 into two additional treatment-resistant indications, including acute myeloid leukemia (AML) and pancreatic cancer.

As BioFuture 2026 convenes in New York, the industry will be watching closely. If Myosin Therapeutics can successfully translate its biomechanical approach from the pages of Cell to the clinics of the Mayo Clinic, it will not only offer a lifeline to patients facing an incurable disease, but it will also fundamentally rewrite the economic and scientific playbook for how we target cancer in the 21st century.